Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic priming using low-dose 5-azazcytidine in diffuse large B-cell lymphoma (MBD-Seq)

ABSTRACT: Epigenetic priming using low-dose 5-azazcytidine in diffuse large B-cell lymphoma (MBD-Seq)

PROVIDER: PRJNA786634 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17148852.fastq.gz	Fastqsanger.gz
	SRR17148853.fastq.gz	Fastqsanger.gz
	SRR17148854.fastq.gz	Fastqsanger.gz
	SRR17148855.fastq.gz	Fastqsanger.gz
	SRR17148856.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Epigenetic priming using low-dose 5-azazcytidine in diffuse large B-cell lymphoma (MBD-Seq)

Project description:MBD sequencing of low-dose 5-azacytidine treated and PBS treated DLBCL cell lines to measure DNA methylation changes

2022-09-27 | GSE190320 | GEO

Epigenetic priming using low-dose 5-azazcytidine in diffuse large B-cell lymphoma

Project description:Epigenetic priming using low-dose 5-azazcytidine in diffuse large B-cell lymphoma

| PRJNA786633 | ENA

Genomic profiling of high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

Project description:The aim of the study was to identify molecular mechanisms involved in high risk diffuse large B-cell lymphomas (diffuse large B-cell lymphomas). <br>51 prospectively collected tumor samples from the patients treated in the Nordic phase II study with dose-dense chemoimmunotherapy followed by systemic CNS prophylaxis were analyzed by high resolution array comparative genomic hybridization (aCGH). <br>The aCGH data were combined with the transcriptomics information from the exon array and the data associated with survival.

2012-03-30 | E-MEXP-3463 | biostudies-arrayexpress

Epigenetic priming using low-dose 5-azazcytidine in diffuse large B-cell lymphoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-09-27 | GSE190321 | GEO

Time-varying expression data from WI38 cell lines that were exposed to a challenge dose with or without a priming dose

Project description:The purpose of this experiment is to elucidate temporal activities and biological processes that can be inferred in response to a 200cGy challenging dose with or without a 10 cGy priming dose in embryonic human fibroblasts The experiment is designed around the human diploid embryonic lung fibroblast cell line WI38 (TP53 proficient), which was grown as a monolayer (2D) under physiological cell culture conditions (3% O2; 10% CO2). Cells are exposed to 2Gy (e.g., the challenge dose) of ionizing radiation (160 kV X-rays) with or without a priming dose of 10cGy (e.g., the adaptive dose) 4 hours prior to the challenge dose. Three biological replicates for each treatment group (e.g., with and without the priming dose) were collected 1, 2, 4 and 8 hours after the challenge dose. The time course was selected on the basis of our prior research on early response to ionizing radiation [1,2]. Purified total cellular RNA was extracted using an RNeasy Mini Kit (Qiagen) and quantified for Affymetrix microarray analysis using Human Gene 1.0 ST Array. Robust multi-array analysis (RMA) was performed to normalize data collected from the different samples. Samples were examined for quality control using the NUSE protocol. Reference [1] Groesser T. et al., Int J of Radiation Research, 2011. 87(7): p. 696-710. Reference [2] Han J. et al., Microscopy, 2010. 241(3): p. 315-326

2012-04-30 | E-GEOD-37668 | biostudies-arrayexpress

Transcription profiling of follicular lymphoma to diffuse large cell lymphoma

Project description:Transformation of Follicular Lymphoma to Diffuse Large Cell Lymphoma: Alternative Patterns with Increased or Decreased Expression of c-myc and its Regulated genes The natural history of follicular lymphoma (FL) is frequently characterized by transformation to a more aggressive diffuse large B cell lymphoma (DLBCL). We compared the gene expression profiles between transformed DLBCL and their antecedent FL. No genes were observed to increase or decrease their expression in all the cases of histological transformation. However, two different gene expression profiles associated with the transformation process were defined, one in which c-myc and genes regulated by c-myc showed increased expression and one in which these same genes showed decreased expression. Further, there was a striking difference in gene expression profiles between transformed DLBCL and de novo DLBCL, since the gene expression profile of transformed DLBCL was more similar to their antecedent FL than to de novo DLBCL. The study demonstrates that transformation from FL to DLBCL can occur by alternative pathways and that transformed DLBCL and de novo DLBCL have very different gene expression profiles that may underlie the different clinical behaviors of these two types of morphologically similar lymphomas.

2005-09-23 | E-SMDB-963 | biostudies-arrayexpress

Diffuse large B-cell lymphoma

Project description:Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in natural history reflects unrecognized molecular heterogeneity in the tumors. Using DNA microarrays, we have conducted a systematic characterization of gene expression in B-cell malignancies. Here we show that there is diversity in gene expression among the tumors of DLBCL patients, apparently reflecting the variation in tumor proliferation rate, host response and differentiation state of the tumor. We identified two molecularly distinct forms of DLBCL which had gene expression patterns indicative of different stages of B-cell differentiation. One type expressed genes characteristic of germinal center B cells ('germinal center B-like DLBCL'); the second type expressed genes normally induced during in vitro activation of peripheral blood B cells ('activated B-like DLBCL'). Patients with germinal center B-like DLBCL had a significantly better overall survival than those with activated B-like DLBCL. The molecular classification of tumors on the basis of gene expression can thus identify previously undetected and clinically significant subtypes of cancer. This study is described more fully in Alizadeh AA et al.(2000) Nature 403:503-11

2002-06-27 | E-GEOD-60 | biostudies-arrayexpress

Time-varying expression data from WI38 cell lines that were exposed to a challenge dose with or without a priming dose

2012-05-01 | GSE37668 | GEO

Diffuse large B-cell lymphoma

2002-06-27 | GSE60 | GEO

Expression profile of diffuse large B cell lymphoma patients

Project description:To understand the biological function of GSTT1 deletion in diffuse large B cell lymphoma (DLBCL), we identified genes that are expressed differently in lymph node tissues from DLBCL patients collected at diagnosis with GSTT1 deletion (4 cases) compared to those without GSTT1 deletion (4 cases).

2016-05-24 | GSE47355 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data